Breast cancer is mostly viewed as a female disease. People often do not know that it can also affect men. Because of the rarity of male brea…read more
Please meet Dr Giuseppe Curigliano, Director, Early Drug Development for Innovative Therapies Division, at the European Institute of Oncolog…read more
Aron Goldhirsch, BIG Vice-chair, was recently conferred the Gianni Bonadonna Breast Cancer Award & Lecture 2014, ASCO Special Award.
BIG against breast cancer would like to introduce you to the talented scientists doing BIG research all over the world. Please meet Dr Alast…read more
Dr. Olivia Pagani is Clinical Director of the Breast Unit of Southern Switzerland and Responsible for Breast Cancer at the Institute of Onc…read more
BIG has now finalised the full AURORA protocol and is setting up all the logistics related to this challenging programme. The programme’s fi…read more
Breast cancer is the most common female malignancy, with about 15% of patients being diagnosed during their reproductive years. Although sev…read more
BIG would like to introduce you to the talented scientists doing BIG research all over the world. In that spirit, BIG will issue, on a regu…read more
IBIS II (International Breast Cancer Prevention Study II) is an international clinical trial supported by the Breast International Group (BI…read more
Great progress has been made, but cancer incidence continues to grow. In Western countries, research and screening programs have successfully reduced the mortality rate but the number of patients diagnosed has actually increased over time (+66% since 1975). Today, a woman’s chance of getting breast cancer is 1 in 8.
Chaired by Dr Martine Piccart and Dr Aron Goldhirsch, BIG’s mission is to facilitate breast cancer research internationally. To fulfil its mission, BIG can count on a network of more than 3.000 hospitals and more than 10.000 doctors and researchers!
AURORA, a Metastatic breast cancer GPS
Academic programme “AURORA” (previously called PRISM-BC)
Metastatic cancer represents the leading cause of death among breast cancer patients, and little progress has been made until now. By using the latest technologies to “molecularly screen” patients tumours, the GPS project aims to analyse the mechanisms of resistance to treatment (why some patients’ tumours respond poorly), to understand the sensitivity to treatment (why some patients’ tumours respond well) and to track the natural progression of the disease. This will be the first large-scale international programme of its kind to focus on metastatic breast cancer, in the hope of significantly improving patients’ lives.
Finding a cure for breast cancer is one of the biggest challenges faced by researchers from around the world.
Significant progress has been made to improve both the chances of survival and the quality of life of women affected by the disease. However, breast cancer remains the second most common cancer in the world and is still responsible for too many deaths annually.
By bringing together the top breast cancer experts from around the world to conduct innovative research, BIG has the global reach and expertise required to find a cure. We need to support such critical research to give hope to women affected by this devastating disease, and their families.
HER MAJESTY THE QUEEN OF THE BELGIANS